The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics

Roy W Jones, Miia Kivipelto, Howard Feldman, Larry Sparks, Rachelle Doody, David D Waters, Judith Hey-Hadavi, Andrei Breazna, Rachel J Schindler, Harry Ramos, LEADe investigators, Peter Passmore

Research output: Contribution to journalArticlepeer-review

53 Citations (Scopus)


Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).
Original languageEnglish
Pages (from-to)145-53
Number of pages9
JournalAlzheimer's & dementia : the journal of the Alzheimer's Association
Issue number2
Publication statusPublished - Mar 2008

ASJC Scopus subject areas

  • Epidemiology
  • Geriatrics and Gerontology
  • Health Policy
  • Clinical Neurology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience


Dive into the research topics of 'The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics'. Together they form a unique fingerprint.

Cite this